bo-1236 and Bacterial-Infections

bo-1236 has been researched along with Bacterial-Infections* in 2 studies

Other Studies

2 other study(ies) available for bo-1236 and Bacterial-Infections

Article	Year
L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals. The Journal of antibiotics, 1989, Volume: 42, Issue:5 The therapeutic activity of L-658,310 was demonstrated in experimental bacteremias in normal, diabetic and neutropenic mice. Especially potent activity was shown against the usually difficult to control pathogens, Enterobacter cloacae and Pseudomonas aeruginosa, that were resistant to ceftazidime and/or gentamicin. Pharmacokinetic studies in mice showed a linear dose response in serum after the 20 and 50 mg/kg subcutaneous dose and urinary recoveries of administered dose of about 60% in 6 hours. Excretion was mainly by glomerular filtration. In a crossover design in rhesus monkeys, the pharmacokinetics of L-658,310 were similar to those of ceftazidime and suggest a moderately long half-life in serum of humans. Topics: Animals; Bacterial Infections; Ceftazidime; Cephalosporins; Diabetes Mellitus, Experimental; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae Infections; Female; Gentamicins; Half-Life; Isoindoles; Macaca mulatta; Male; Mice; Neutropenia; Pseudomonas Infections	1989
Biological activity of BO-1236, a new antipseudomonal cephalosporin. Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:7 BO-1236, a new cephalosporin having an N-methyl-5,6-dihydroxyisoindolinium moiety on the 3-methylene of the cephem, showed potent activity against gram-negative organisms, including Pseudomonas aeruginosa. The in vitro activity of BO-1236 was superior or comparable to that of ceftazidime, cefotaxime, and cefoperazone in susceptibility tests with clinical isolates. BO-1236 was significantly more active than ceftazidime against P. aeruginosa strains susceptible or resistant to ceftazidime or gentamicin or both. MBCs were usually close to MICs, both of which were influenced by inoculum size to about the same degree as those of the other beta-lactams. BO-1236 was stable to all types of beta-lactamases except type I oxyiminocephalosporin-hydrolyzing enzyme, by which BO-1236 was slightly hydrolyzed. BO-1236 showed protective activity superior to that of ceftazidime and cefotaxime in experimental infections in mice caused by two strains of P. aeruginosa and showed activity comparable to that of ceftazidime and cefotaxime against other gram-negative bacterial infections. Topics: Animals; Bacterial Infections; beta-Lactamases; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Chemical Phenomena; Chemistry; Gram-Negative Bacteria; Gram-Positive Bacteria; Isoindoles; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa	1987

Article

Year

L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.

The Journal of antibiotics, 1989, Volume: 42, Issue:5

The therapeutic activity of L-658,310 was demonstrated in experimental bacteremias in normal, diabetic and neutropenic mice. Especially potent activity was shown against the usually difficult to control pathogens, Enterobacter cloacae and Pseudomonas aeruginosa, that were resistant to ceftazidime and/or gentamicin. Pharmacokinetic studies in mice showed a linear dose response in serum after the 20 and 50 mg/kg subcutaneous dose and urinary recoveries of administered dose of about 60% in 6 hours. Excretion was mainly by glomerular filtration. In a crossover design in rhesus monkeys, the pharmacokinetics of L-658,310 were similar to those of ceftazidime and suggest a moderately long half-life in serum of humans.

Topics: Animals; Bacterial Infections; Ceftazidime; Cephalosporins; Diabetes Mellitus, Experimental; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae Infections; Female; Gentamicins; Half-Life; Isoindoles; Macaca mulatta; Male; Mice; Neutropenia; Pseudomonas Infections

1989

Biological activity of BO-1236, a new antipseudomonal cephalosporin.

Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:7

BO-1236, a new cephalosporin having an N-methyl-5,6-dihydroxyisoindolinium moiety on the 3-methylene of the cephem, showed potent activity against gram-negative organisms, including Pseudomonas aeruginosa. The in vitro activity of BO-1236 was superior or comparable to that of ceftazidime, cefotaxime, and cefoperazone in susceptibility tests with clinical isolates. BO-1236 was significantly more active than ceftazidime against P. aeruginosa strains susceptible or resistant to ceftazidime or gentamicin or both. MBCs were usually close to MICs, both of which were influenced by inoculum size to about the same degree as those of the other beta-lactams. BO-1236 was stable to all types of beta-lactamases except type I oxyiminocephalosporin-hydrolyzing enzyme, by which BO-1236 was slightly hydrolyzed. BO-1236 showed protective activity superior to that of ceftazidime and cefotaxime in experimental infections in mice caused by two strains of P. aeruginosa and showed activity comparable to that of ceftazidime and cefotaxime against other gram-negative bacterial infections.

Topics: Animals; Bacterial Infections; beta-Lactamases; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Chemical Phenomena; Chemistry; Gram-Negative Bacteria; Gram-Positive Bacteria; Isoindoles; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa

1987